投资者可以起诉Neumora治疗公司,指控其伪造心理健康药物试验中的数据。 Investors may sue Neumora Therapeutics for allegedly falsifying data in mental health drug trials.

尼莫拉治疗公司的投资者可能会加入诉讼, 声称公司对其第二期和第三期试验做出了虚假陈述, Neumora Therapeutics investors may join a lawsuit alleging the company made false statements about its Phase Two and Three trials, including altering inclusion criteria and statistical analysis to present a more favorable view of their MDD treatment. 2023年9月购买股票的投资者直到2025年4月7日才加入诉讼并要求赔偿潜在的资金损失。 Investors who bought stock in the September 2023 IPO have until April 7, 2025, to join the suit and seek compensation for potential financial losses. 多家律师事务所在本案中代表股东。 Multiple law firms are representing shareholders in this case.